Indivior PLC 8-K filings

Indivior PLC announced its intention to cancel its secondary listing on the London Stock Exchange, effective July 25, 2025, to consolidate its primary listing on Nasdaq, citing U.S. revenue focus and higher Nasdaq liquidity.

Indivior PLC has amended the vote tally for the election of Dr. David Wheadon at its 2025 Annual General Meeting (AGM), with all other details remaining unchanged.

Indivior PLC held its 2025 Annual General Meeting on May 8, 2025, with all resolutions duly passed by shareholders.

Indivior PLC reports first quarter 2025 results, with total net revenue of $266 million and reaffirms its FY 2025 guidance.

Indivior is seeking shareholder approval for a revised Directors Remuneration Policy at its upcoming Annual General Meeting to attract and retain top talent, particularly in the competitive US biopharmaceutical market, and to align CEO compensation with shareholder value creation.

Indivior PLC announces the appointment of Joe Ciaffoni as CEO, along with several board changes and an amended agreement with Oaktree Capital Management.